<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-32503-2S2UI</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">HIV Intellectual Property Amplified (HIPA): Challenging intellectual property barriers that prevent access to treatment for PLHIV in Zimbabwe</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">In 1994 all members of the World Trade Organisation (WTO) including Zimbabwe adopted the Trade Related Aspects on Intellectual Property Rights known as the TRIPS Agreement. The TRIPS Agreement obliged all WTO members, including developing countries, to grant patents on, among other fields of technology, pharmaceutical products. This was subsequently followed by the Doha Declaration in 2001. The Doha Declaration acknowledged the rights of countries to protect public health in the light of the HIV and AIDS pandemic, as a &#x2018;national emergency&#x2019;. In the area of health, these flexibilities have come to be commonly known as &#x201C;public health TRIPS Flexibilities&#x201D;. There was a particular emphasis on the need to promote wider availability of lower cost generic medicines to ensure sustained availability and access to treatment. The Doha Declaration confirmed that public health considerations can and should condition the extent to which patents on pharmaceuticals are enforced and that flexibilities in the TRIPS Agreement should be used to improve access to medicines for all. The key barriers that Zimbabwe face include knowledge gaps (at policy, implementation and user level) on how to implement different provisions of the TRIPS flexibilities, challenges related to using compulsory licenses and insufficient manufacturing capacity in the pharmaceutical sector (due to a mix of exorbitant cost of production and high royalties and duties on the active ingredients). However, the key barrier is the capacity of PLHIV to understand and support advocacy around the IP barriers to access to treatment. ZNNP+ seeks to roll out a project on raising awareness on intellectual property barriers on access to treatment to people living with HIV (HIPA Project). The project will be conducted for 3 years throughout the country targeting policy makers (parliamentary and sub-committee members), implementers (government ministries and departments) and pharmaceutical companies.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">OUTCOMES
* Improved access to patented HIV (raltegravir, ritonavir, etravirine and dolutegravir), TB and STI medicines at local, national and regional level due to a change in IP policy or implementation of IP policy.
* Policies reflecting the perspectives of people living with HIV, through IP policy adaptation and the introduction of new regulations.
* Expanded networks, stakeholders are connected for collaborative TRIPS advocacy.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">Zimbabwe has about 1,4 million PLHIV. Of these 1.4 million only 1 million people living with HIV are on ART.  ZNNP+ envisages that this population will benefit directly from the programme</narrative>
  </description>
  <description type="4">
   <narrative xml:lang="EN">Zimbabwe&apos;s main barrier is the limited capacity of PLHIV to understand and support advocacy around the IP barriers to access to treatment. Other barriers that Zimbabwe faces include knowledge gaps at policy, implementation and user level on how to implement different provisions of the TRIPS flexibilities. Compulsory licensing and addressing the insufficient manufacturing capacity is essential, since limited availability of medicine can be explained by a mix of high production costs and high royalties medicine ingredients.</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">ZNNP+</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2018-01-01" type="2"></activity-date>
  <activity-date iso-date="2021-07-01" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
   </organisation>
   <email>IATI@aidsfonds.nl</email>
   <website>https://aidsfonds.nl/</website>
   <mailing-address>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland, Condensatorweg 54, 1014 AX Amsterdam</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="ZW" percentage="34"></recipient-country>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C39" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2021-07-01"></period-end>
   <value currency="EUR" value-date="2018-01-01">205747</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-11-29"></transaction-date>
   <value currency="EUR" value-date="2021-11-29">9864</value>
   <description>
    <narrative xml:lang="EN">Final commitment</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-03-20"></transaction-date>
   <value currency="EUR" value-date="2018-03-20">20000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-03-21"></transaction-date>
   <value currency="EUR" value-date="2018-03-21">20000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-07-23"></transaction-date>
   <value currency="EUR" value-date="2018-07-23">20000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-07-24"></transaction-date>
   <value currency="EUR" value-date="2018-07-24">20000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-11-21"></transaction-date>
   <value currency="EUR" value-date="2018-11-21">20000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-11-21"></transaction-date>
   <value currency="EUR" value-date="2018-11-21">20000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-04-24"></transaction-date>
   <value currency="EUR" value-date="2019-04-24">26122</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-04-25"></transaction-date>
   <value currency="EUR" value-date="2019-04-25">26122</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-07-24"></transaction-date>
   <value currency="EUR" value-date="2019-07-24">14189</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-07-25"></transaction-date>
   <value currency="EUR" value-date="2019-07-25">14189</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-12-17"></transaction-date>
   <value currency="EUR" value-date="2019-12-17">14000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-17"></transaction-date>
   <value currency="EUR" value-date="2019-12-17">14000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-05-21"></transaction-date>
   <value currency="EUR" value-date="2020-05-21">21000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-05-22"></transaction-date>
   <value currency="EUR" value-date="2020-05-22">21000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-11-28"></transaction-date>
   <value currency="EUR" value-date="2020-11-28">26689</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-11-28"></transaction-date>
   <value currency="EUR" value-date="2020-11-28">26689</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">ZNNP+</narrative>
   </receiver-org>
  </transaction>
  <related-activity ref="NL-KVK-41207989-P-28901-2S2UI" type="1"></related-activity>
 </iati-activity>
</iati-activities>
